- To review the role of new biomarkers and staging systems for the development of disease-modifying therapies in HD
- To discuss somatic instability and other epigenetics impacting our understanding of the pathophysiology of HD
- To review topline data releases for key clinical trials including ASO's, gene therapy, and splicing modifiers in HD

Session date: 
03/05/2025 - 8:00am to 9:00am CST
Location: 
UT Southwestern Medical Center
Dallas, TX
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AMA
  • 1.00 Attendance

Please login or create an account to take this course.